{"created":"2021-03-01T06:34:24.437194+00:00","id":28580,"links":{},"metadata":{"_buckets":{"deposit":"c89dc557-114d-48e6-9186-e446ae3d2a1b"},"_deposit":{"id":"28580","owners":[],"pid":{"revision_id":0,"type":"depid","value":"28580"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00028580"},"item_7_alternative_title_1":{"attribute_name":"\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_alternative_title":"Effects of anti-IL-12/IL-23p40 monoclonal antibody \uff08ustekinumab\uff09 on tumor antigen-specific cytotoxic T lymphocytes \uff08CTLs\uff09"}]},"item_7_biblio_info_6":{"attribute_name":"\u66f8\u8a8c\u60c5\u5831","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"82","bibliographicPageStart":"75","bibliographicVolumeNumber":"11","bibliographic_titles":[{"bibliographic_title":"\u65b0\u6f5f\u5927\u5b66\u4fdd\u5065\u5b66\u96d1\u8a8c"},{"bibliographic_title":"\u65b0\u6f5f\u5927\u5b66\u4fdd\u5065\u5b66\u96d1\u8a8c","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"\u6284\u9332","attribute_value_mlt":[{"subitem_description":"\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306f\u30d2\u30c8\u578b\u6297\u30d2\u30c8 interleukin\uff08IL\uff09-12/IL-23p40\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u5264\u3067\u3042\u308a\uff0c\u4e7e\u766c\u306e\u6cbb\u7642\u306b\u7528\u3044\u3089\u308c\u3066\u3044\u308b\u3002\u3057\u304b\u3057\uff0cIL-12\u306f\u6297\u816b\u760d\u514d\u75ab\u306b\u304a\u3044\u3066\u91cd\u8981\u306a\u5f79\u5272\u3092\u62c5\u3046\u305f\u3081\uff0c\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306b\u3088\u308b\u816b\u760d\u767a\u751f\u7387\u306e\u5897\u52a0\u304c\u61f8\u5ff5\u3055\u308c\u3066\u3044\u308b\u3002\u4eca\u56de\u306e\u691c\u8a0e\u3067\u306f\uff0c\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u6297\u539f\u7279\u7570\u7684\u764c\u514d\u75ab\u306b\u304a\u3051\u308b\u5f71\u97ff\u3092\u660e\u3089\u304b\u306b\u3059\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u305f\u3002\u4e7e\u766c\u60a3\u8005\u306b\u5bfe\u3059\u308b in vivo \u306e\u691c\u8a0e\u3067\u306f\uff0c\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u6295\u4e0e\u306b\u3088\u308a\u4e7e\u766c\u75c7\u72b6\u306f\u6539\u5584\u3055\u308c\u305f\u304c\uff0c\u816b\u760d\u6297\u539f\u7279\u7570\u7684\u7d30\u80de\u50b7\u5bb3\u6027 T \u7d30\u80de\uff08CTL\uff09\u306e frequency \u306f\u6295\u4e0e\u958b\u59cb\u4ee5\u964d\u3082\u6291\u5236\u3055\u308c\u308b\u3053\u3068\u306f\u306a\u304b\u3063\u305f\u3002\u307e\u305f in vitro \u306e\u691c\u8a0e\u3067\u306f\uff0c\u6a39\u72b6\u7d30\u80de\u306e\u6297\u539f\u63d0\u793a\u80fd\u53ca\u3073\u6297\u539f\u7279\u7570\u7684 CTL \u306e\u8a98\u5c0e\u306b\u5bfe\u3059\u308b\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u6291\u5236\u52b9\u679c\u306f\u78ba\u8a8d\u3067\u304d\u306a\u304b\u3063\u305f\u3002\u3053\u308c\u3089\u306e\u7d50\u679c\u304b\u3089\uff0c\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306f\u6a39\u72b6\u7d30\u80de\u306e\u6a5f\u80fd\u3084\u816b\u760d\u6297\u539f\u7279\u7570\u7684 CTL \u306e\u8a98\u5c0e\u3092\u6291\u5236\u3059\u308b\u3053\u3068\u306a\u304f\u4e7e\u766c\u75c7\u72b6\u3092\u6539\u5584\u3059\u308b\u3053\u3068\u304c\u53ef\u80fd\u3067\u3042\u308a\uff0c\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u6cbb\u7642\u75c7\u4f8b\u306b\u304a\u3051\u308b\u816b\u760d\u767a\u75c7\u306e\u5897\u52a0\u306f\u898b\u3089\u308c\u306a\u3044\u3068\u3044\u3046\u6700\u8fd1\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u77e5\u898b\u3092\u652f\u6301\u3059\u308b\u3082\u306e\u3068\u8003\u3048\u3089\u308c\u305f\u3002","subitem_description_type":"Abstract"},{"subitem_description":"Ustekinumab \uff08a humanized monoclonal antibody against the common p40 subunit shared by IL-12 andIL-23\uff09 blocks the pathways of T helper \uff08Th\uff09-1 and Th-17, which play pivotal roles in cell-mediated immunity and production of pro-inflammatory cytokines. Ustekinumab is currently used for the treatment of moderate to severe psoriasis with remarkable efficiency. However, worries about the development of malignancies in ustekinumab-treated patients could not be completely cleared because of the major role of IL-12 and IL-23 in tumor immunity. In the present study, we tried to elucidate the effects of ustekinumab on antigen-specific tumor immunity. A 56 years-old male volunteer was subcutaneously administered with 20 times of WT1 peptide. WT1 tetramer+ CD8+ T cells appeared after the first peptide administration and the frequency of WT1 tetramer+ T cells elevated to more than 15 in 10^6 CD8+ T cells. He began to be treated with subcutaneous injections of ustekinumab for moderate psoriasis. Psoriasis plaques were almost cleared up at week 12. The frequency of WT1 tetramer+ T cells with cytotoxic ability has not changed for 22 months since the initiation of ustekinumab treatment. The effects of ustekinumab on antigen presenting and CTL inducing abilities of dendritic cells were explored in vitro, resulting in little effects on both immune functions. These in vivo/vitro findings imply that ustekinumab improves psoriasis without suppressing tumor antigen-specific cytotoxic T lymphocytes and support the data of recent clinical trials showing a comparable incidence of malignancies between ustekinumab-treated psoriatic patients and the control.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"\u8457\u8005\u5225\u540d","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"164564","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Nishizawa, Yoshinori"}]},{"nameIdentifiers":[{"nameIdentifier":"164565","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Narita, Miwako"}]},{"nameIdentifiers":[{"nameIdentifier":"164566","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Iwaya, Shunpei"}]},{"nameIdentifiers":[{"nameIdentifier":"164567","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Oiwa, Eri"}]},{"nameIdentifiers":[{"nameIdentifier":"164568","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Iwabuchi, Minami"}]},{"nameIdentifiers":[{"nameIdentifier":"164569","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Uchiyama, Takayoshi"}]},{"nameIdentifiers":[{"nameIdentifier":"164570","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Matsuyama, Asako"}]},{"nameIdentifiers":[{"nameIdentifier":"164571","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Takahashi, Masuhiro"}]}]},"item_7_publisher_7":{"attribute_name":"\u51fa\u7248\u8005","attribute_value_mlt":[{"subitem_publisher":"\u65b0\u6f5f\u5927\u5b66\u533b\u5b66\u90e8\u4fdd\u5065\u5b66\u79d1"}]},"item_7_select_19":{"attribute_name":"\u8457\u8005\u7248\u30d5\u30e9\u30b0","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID","attribute_value_mlt":[{"subitem_source_identifier":"AA12680484","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"21884617","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"\u8457\u8005","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"\u897f\u6fa4, \u5e79\u5247"}],"nameIdentifiers":[{"nameIdentifier":"164556","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u6210\u7530, \u7f8e\u548c\u5b50"}],"nameIdentifiers":[{"nameIdentifier":"164557","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u5ca9\u8c37, \u4fca\u5e73"}],"nameIdentifiers":[{"nameIdentifier":"164558","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u5927\u5ca9, \u6075\u7406"}],"nameIdentifiers":[{"nameIdentifier":"164559","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u5ca9\u6e15, \u5357"}],"nameIdentifiers":[{"nameIdentifier":"164560","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u5185\u5c71, \u5b5d\u7531"}],"nameIdentifiers":[{"nameIdentifier":"164561","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u677e\u5c71, \u9ebb\u5b50"}],"nameIdentifiers":[{"nameIdentifier":"164562","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"\u9ad8\u6a4b, \u76ca\u5ee3"}],"nameIdentifiers":[{"nameIdentifier":"164563","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"\u30d5\u30a1\u30a4\u30eb\u60c5\u5831","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-20"}],"displaytype":"detail","filename":"11(1)_75-82.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"11(1)_75-82.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/28580/files/11(1)_75-82.pdf"},"version_id":"292e094d-0306-45c8-80ae-76551578167a"}]},"item_keyword":{"attribute_name":"\u30ad\u30fc\u30ef\u30fc\u30c9","attribute_value_mlt":[{"subitem_subject":"\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6","subitem_subject_scheme":"Other"},{"subitem_subject":"\u4e7e\u766c","subitem_subject_scheme":"Other"},{"subitem_subject":"\u6297\u539f\u7279\u7570\u7684\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de","subitem_subject_scheme":"Other"},{"subitem_subject":"\u6a39\u72b6\u7d30\u80de","subitem_subject_scheme":"Other"},{"subitem_subject":"\u6297\u816b\u760d\u514d\u75ab","subitem_subject_scheme":"Other"},{"subitem_subject":"Ustekinumab","subitem_subject_scheme":"Other"},{"subitem_subject":"Psoriasis","subitem_subject_scheme":"Other"},{"subitem_subject":"Antigen specific cytotoxic T lymphocytes","subitem_subject_scheme":"Other"},{"subitem_subject":"Dendritic cells","subitem_subject_scheme":"Other"},{"subitem_subject":"Anti-tumor immunity","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"\u8a00\u8a9e","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"\u8cc7\u6e90\u30bf\u30a4\u30d7","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"IL-12/IL-23p40\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u5264\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u816b\u760d\u6297\u539f\u7279\u7570\u7684\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de \uff08CTL\uff09 \u306b\u5bfe\u3059\u308b\u5f71\u97ff","item_titles":{"attribute_name":"\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_title":"IL-12/IL-23p40\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u5264\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u816b\u760d\u6297\u539f\u7279\u7570\u7684\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de \uff08CTL\uff09 \u306b\u5bfe\u3059\u308b\u5f71\u97ff"},{"subitem_title":"IL-12/IL-23p40\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u5264\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u816b\u760d\u6297\u539f\u7279\u7570\u7684\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de \uff08CTL\uff09 \u306b\u5bfe\u3059\u308b\u5f71\u97ff","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["453/456","506/1624/1625/1630"],"pubdate":{"attribute_name":"\u516c\u958b\u65e5","attribute_value":"2016-02-29"},"publish_date":"2016-02-29","publish_status":"0","recid":"28580","relation_version_is_last":true,"title":["IL-12/IL-23p40\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u88fd\u5264\u30a6\u30b9\u30c6\u30ad\u30cc\u30de\u30d6\u306e\u816b\u760d\u6297\u539f\u7279\u7570\u7684\u7d30\u80de\u50b7\u5bb3\u6027T\u7d30\u80de \uff08CTL\uff09 \u306b\u5bfe\u3059\u308b\u5f71\u97ff"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2021-03-01T10:56:56.062331+00:00"}